EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC-ND 4.0

The Aspergillus galactomannan Ag VIRCLIA ® Monotest and the sõna Aspergillus galactomannan lateral flow assay show comparable performance for the diagnosis of invasive aspergillosis

Corinna Küpper, Timothy Moritz Erb, Johannes Träger, Lisa Meintker, Giuseppe Valenza, Christian Bogdan, Jürgen Held iD

Mycoses · 2024

DOI: 10.1111/myc.13782 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Mycoses, 2024. Verfasst von Corinna Küpper und 6 weiteren Autor:innen. Beteiligte Einrichtung: Mikrobiologisches Institut-Klinische Mikrobiologie, Immunologie und Hygiene, Universitätsklinikum Erlangen und Friedrich-Alexander-Universität (FAU) …. Hauptthemen laut MEDLINE: Mannans, Galactose, Sensitivity and Specificity, Aspergillus. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Rapid galactomannan tests, such as the sõna Aspergillus GM Lateral Flow Assay (GM‐LFA) and the Aspergillus Galactomannan Ag VIRCLIA® Monotest (GM‐Monotest), which are suitable for the analysis of single samples, have the potential to accelerate diagnosis of invasive aspergillosis (IA).

Objectives

To compare the performance of the GM‐Monotest and the GM‐LFA for the diagnosis of IA. Patients/Methods Two patient cohorts were analysed: adults who had received an allogeneic haematopoietic stem‐cell transplant (alloHSCT‐cohort) and patients with proven/probable IA from a 5‐year period (cross‐sectional IA‐cohort). In the alloHSCT‐cohort, weekly serum samples were tested, whereas in the cross‐sectional IA‐cohort sera and bronchoalveolar lavage fluids were analysed. The diagnostic performance was calculated using two definitions for positivity: (1) a single positive GM result and (2) at least two positive GM results from consecutive samples. IA classification followed EORTC/MSG 2019.

Results

The alloHSCT‐cohort included 101 patients. Four had proven/probable IA, 26 possible IA and 71 no IA. The specificity for one positive serum and two consecutively positive sera was 88.7% and 100% (GM‐Monotest) and 85.9% and 98.6% (GM‐LFA). Comparison of ROC curves in the alloHSCT‐cohort showed no significant difference. The cross‐sectional IA‐cohort included 59 patients with proven/probable IA. The sensitivity for one positive sample and two consecutively positive samples was 83.1% and 55.1% (GM‐Monotest) and 86.4% and 71.4% (GM‐LFA).

Conclusions

Both assays showed comparable diagnostic performance with a higher sensitivity for the GM‐LFA if two consecutive positive samples were required for positivity. However, due to poor reproducibility, positive GM‐LFA results should always be confirmed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MannansGalactoseSensitivity and SpecificityAspergillusHumansMaleMiddle AgedFemaleCross-Sectional StudiesAdultAgedInvasive Pulmonary AspergillosisAntigens, FungalBronchoalveolar Lavage FluidImmunoassayHematopoietic Stem Cell TransplantationAspergillosisCohort StudiesYoung Adult

Stichwörter der Autor:innen

POCTPlateliaantigeninvasive fungal diseaseinvasive fungal infectionpoint‐of‐care test

Substanzen

MannansgalactomannanGalactoseAntigens, Fungal

Autor:innen und Institutionen

  • Mikrobiologisches Institut-Klinische Mikrobiologie, Immunologie und Hygiene, Universitätsklinikum Erlangen und Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Erlangen, Germany.
  • Department für Hämatologie/Onkologie, Medizinische Klinik 5, Universitätsklinikum Erlangen und Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Erlangen, Germany.
  • FAU Profile Center for Immunomedicine, FAU Erlangen-Nürnberg, Erlangen, Germany.

ORCID-Profile: Jürgen Held

Zitieren

APA

Küpper, C., Erb, T. M., Träger, J., Meintker, L., Valenza, G., Bogdan, C., & Held, J. (2024). The Aspergillus galactomannan Ag VIRCLIA ® Monotest and the sõna Aspergillus galactomannan lateral flow assay show comparable performance for the diagnosis of invasive aspergillosis. Mycoses. https://doi.org/10.1111/myc.13782

Vancouver

Küpper C, Erb TM, Träger J, Meintker L, Valenza G, Bogdan C, et al. The Aspergillus galactomannan Ag VIRCLIA ® Monotest and the sõna Aspergillus galactomannan lateral flow assay show comparable performance for the diagnosis of invasive aspergillosis. Mycoses. 2024. doi:10.1111/myc.13782

BibTeX
@article{Kpper2024,
  author = {Küpper, Corinna and Erb, Timothy Moritz and Träger, Johannes and Meintker, Lisa and Valenza, Giuseppe and Bogdan, Christian and Held, Jürgen},
  title = {The Aspergillus galactomannan Ag VIRCLIA ® Monotest and the sõna Aspergillus galactomannan lateral flow assay show comparable performance for the diagnosis of invasive aspergillosis},
  journal = {Mycoses},
  year = {2024},
  doi = {10.1111/myc.13782}
}
Kostenlos starten →